Literature DB >> 31436225

Apatinib for hepatocellular carcinoma.

Yang Ni1, Xin Ye1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31436225     DOI: 10.4103/jcrt.JCRT_400_19

Source DB:  PubMed          Journal:  J Cancer Res Ther        ISSN: 1998-4138            Impact factor:   1.805


× No keyword cloud information.
  2 in total

1.  Apatinib inhibits paclitaxel resistance of gastric carcinoma cells through VEGFR2 pathway.

Authors:  Qian Xie; Jing Wang; Wenwen Wu; Ye Zhao
Journal:  Am J Transl Res       Date:  2022-01-15       Impact factor: 4.060

2.  The efficacy and safety of Apatinib combined with TACE in the treatment of hepatocellular carcinoma: a meta-analysis.

Authors:  Anan Gong; Xiaofei Li
Journal:  World J Surg Oncol       Date:  2022-03-04       Impact factor: 2.754

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.